Evaluation of combinational effect of Aprepitant on nausea and vomiting induced by chemotherapy (moderate risk) in patients with Gastric Cancer or Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2623451
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Group A: * 1st course : Conventional therapy (Palonosetron 0.75 mg i.v. on 1st day + Dexamathasone 9.9 mg i.v. on 1st day, 8 mg p.o. on 2nd day and 3rd day) * 2nd course : Conventional therapy (Palonosetron 0.75 mg i.v. on 1st day + Dexamathasone 4.95 mg i.v. on 1st day, 4 mg p.o. on 2nd day and 3rd day) plus Aprepitant (125 mg p.o. on 1st day, 80 mg p.o. on 2nd day and 3rd day)
Group B: * 1st course: Conventional therapy (Palonosetron 0.75 mg i.v. on 1st day + Dexamathasone 4.95 mg i.v. on 1st day, 4 mg p.o. on 2nd day and 3rd day) plus Aprepitant (125 mg p.o. on 1st day, 80 mg p.o. on 2nd day and 3rd day) * 2nd course : Conventional therapy (Palonosetron 0.75 mg i.v. on 1st day + Dexamathasone 9.9 mg i.v. on 1st day, 8 mg p.o. on 2nd day and 3rd day)
Primary outcome(s): * Frequency of vomiting * Severity of nausea
Study Design: Cross-over Randomized
创建时间：
2012-02-15
